| 1 |
Weiss A, Hendrickx R, Stensgaard E, et al. Kidney transplant and dialysis patients remain at increased risk for succumbing to COVID-19[J]. Transplantation, 2023，107(5)：1136-1138.
|
| 2 |
Brogan M, Ross MJ. COVID-19 and kidney disease[J]. Annu Rev Med，2022, 74：1-13.
|
| 3 |
Lansbury L, Lim B, Baskaran V, et al. Co-infections in people with COVID-19: a systematic review and meta-analysis[J]. J Infect, 2020，81(2)：266-275.
|
| 4 |
Miyashita N, Nakamori Y, Ogata M, et al. Clinical differences between community-acquired mycoplasma pneumoniae pneumonia and COVID-19 pneumonia[J]. J Clin Med, 2022, 11(4)：964.
|
| 5 |
Amin D, McKitish K, Shah PS. Association of mortality and recent Mycoplasma pneumoniae infection in COVID-19 patients[J]. J Med Virol, 2021，93(2)：1180-1183.
|
| 6 |
Shimizu T. Inflammation-inducing factors of mycoplasma pneumoniae[J]. Front Microbiol, 2016，7：414.
|
| 7 |
Waites KB, Xiao L, Liu Y, et al. Mycoplasma pneumoniae from the Respiratory Tract and Beyond[J]. Clin Microbiol Rev, 2017，30(3)：747-809.
|
| 8 |
Ye Q, Wang B, Mao J. The pathogenesis and treatment of the 'Cytokine Storm' in COVID-19[J]. J Infect, 2020，80(6)：607-613.
|
| 9 |
Henderson LA, Canna SW, Schulert GS, et al. On the alert for cytokine storm: immunopathology in COVID-19[J]. Arthritis Rheumatol, 2020，72(7)：1059-1063.
|
| 10 |
Zhou Y, Fu B, Zheng X, et al. Pathogenic T-cells and inflammatory monocytes incite inflammatory storms in severe COVID-19 patients[J]. Natl Sci Rev, 2020，7(6)：998-1002.
|
| 11 |
Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China[J]. Lancet, 2020, 395(10223)：497-506.
|
| 12 |
Zhang W, Zhao Y, Zhang F, et al. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019(COVID-19)：the perspectives of clinical immunologists from China[J]. Clin Immunol, 2020, 214：108393.
|
| 13 |
Ren Z, Luo H, Yu Z, et al. A randomized, open-label, controlled clinical trial of azvudine tablets in the treatment of mild and common COVID-19, a pilot study[J]. Adv Sci(Weinh), 2020，7(19)：e2001435.
|
| 14 |
Sun Y, Jin L, Dian Y, et al. Oral Azvudine for hospitalised patients with COVID-19 and pre-existing conditions: a retrospective cohort study[J]. EClinicalMedicine, 2023, 59：101981.
|
| 15 |
Zhang JL, Li YH, Wang LL, et al. Azvudine is a thymus-homing anti-SARS-CoV-2 drug effective in treating COVID-19 patients[J]. Signal Transduct Target Ther, 2021，6(1)：414.
|
| 16 |
Chen Zhaoyan, Tian Fangyuan. Efficacy and safety of azvudine in patients with COVID-19: a systematic review and meta-analysis[J]. Heliyon, 2023，9(9): e20153.
|
| 17 |
国家传染病医学中心，中华医学会器官移植学分会，中国康复医学会器官移植康复专业委员会，等. 实体器官移植受者新冠病毒感染诊疗专家共识(2023年版)[J/CD]，中华移植杂志：电子版，2023, 17(2): 65-81.
|
| 18 |
Rahi MS, Jindal V, Reyes SP, et al. Hematologic disorders associated with COVID-19: a review[J]. Ann Hematol, 2021，100(2)：309-320.
|
| 19 |
Jones HP, Simecka JW. T lymphocyte responses are critical determinants in the pathogenesis and resistance to mycoplasma respiratory disease[J]. Front Biosci, 2003, 8: d930-45.
|
| 20 |
Dobbs NA, Odeh AN, Sun X, et al. The multifaceted role of T cell-mediated immunity in pathogenesis and resistance to mycoplasma respiratory disease[J]. Curr Trends Immunol, 2009，10：1-19.
|
| 21 |
Gao M, Wang K, Yang M, et al. Transcriptome analysis of bronchoalveolar lavage fluid from children with mycoplasma pneumoniae pneumonia reveals natural killer and T cell-proliferation responses[J]. Front Immunol, 2018，9：1403.
|